Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Slides:

Advertisements

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Advertisements

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

Diabetes hazard rates by number of visits with reported statin use.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

Kaplan-Meier curves for overall survival (OS) probability.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

(A) Quality of life scores in individuals with and without constipation. (A) Quality of life scores in individuals with and without constipation. (B) Quality.

Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Enrollment and Outcomes

(A–C) Time-course changes in morning time fasted, and daytime (A) IL-6, (B) TNF-α, and (C) β-hydroxybutyrate concentrations. (A–C) Time-course changes.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Geographic areas with increased ED visits after Hurricane Sandy by diabetic adults. Geographic areas with increased ED visits after Hurricane Sandy by.

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Scatterplot showing the association between baseline weight and weight change at 1 year, relative to baseline for each treatment group. Scatterplot showing.

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Calibration plot by quintiles of predicted 5-year diabetes risk of the comprehensive German Diabetes Risk Score (GDRS) for prediction of incident diagnosed.

Age-standardized probability of finding undiagnosed diabetes among the US population without diagnosed diabetes aged ≥18 years by survey cycle. Age-standardized.

Daily changes in ED use compared to baseline utilization in October and November 2012 for patients with diabetes in New York City evacuation zone level.

Subgroup analysis of physical activity rates—Asian immigrants versus whites stratified by DM status. Subgroup analysis of physical activity rates—Asian.

Comparison of prevalence of diabetes mellitus in relation to quartile of serum selenium levels. Comparison of prevalence of diabetes mellitus in relation.

Yearly trends in percentage of admissions for primary TB cases that occurred in selected high-risk groups from 1992 to 2011: secondary diagnoses of HIV.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

(A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group). (A) T2DM: serum glucose levels during glucose tolerance test (n=6 per group).

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Correlation between plasma C reactive protein (CRP) and angiopoietin-like protein 4 (ANGPTL4). Correlation between plasma C reactive protein (CRP) and.

(A) Serum CRP levels. (A) Serum CRP levels. T2DM: n=6 per group. *p

Change in %A1C over 5 years in response to 12-week intensive lifestyle intervention used in a real-world clinical practice. Change in %A1C over 5 years.

Age-adjusted and sex-adjusted prevalence of diabetes of Asian immigrants and whites in California from 2003 to Age-adjusted and sex-adjusted prevalence.

Calibration plots for the clinical GDRS in the EPIC-Potsdam study (A) and the GNHIES98 cohort (B). Predicted risks were determined using score points,

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Change in (A) systolic blood pressure and (B) diastolic blood pressure over 5 years in response to 12-week intensive lifestyle intervention in a real-world.

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Sensitivity analysis: random-effects model of the risk of lower extremity amputation (LEA) in people with diabetes associated with depression compared.

Mean (95% CI) fasting s-glucose at baseline and 6-month, 12-month, and 24-month follow-up, overall and by sex (A), and by baseline age (B), education (C),

(A) Glucose values (mean +SEM) during continuous glucose monitoring while consuming whey protein (solid lines and filled circles) or placebo (broken lines.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Homeostasis model assessment of insulin resistance (HOMA-IR) scores in obese women and obese women with gestational diabetes mellitus (GDM) at approximately.

Mean decline in grip strength with aging by baseline quartile of fasting plasma glucose (FPG). Mean decline in grip strength with aging by baseline quartile.

Serum adiponectin is significantly lower in obese gestational diabetes mellitus (GDM) women compared with obese women at 26 weeks of gestation. Serum adiponectin.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Continuous associations

Receiver-operating characteristic curves showing the performance of the diabetes risk score in predicting diabetes in the United Arab Emirates (UAE) citizens.

Categorical A1c distribution within BMI categories, n=414 266 patients with T2D and available A1c data. % values represent percentage of subjects within.

Kaplan-Meier curves depicting the probability of survival from study enrollment in patients receiving conventional chest physical therapy (CCPT) (solid.

Stages of change for physical activity and dietary habits and associations with self-management scores (A) and HRQL scores (B). heiQ, Health Education.

Mean decline in grip strength with aging is shown for participants categorized by baseline quartile of 2 h glucose (2HG). Mean decline in grip strength.

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Insulin sensitivity (Si-clamp) in obese and non-obese study subjects (A) and cumulative incidence of pre-diabetes/type 2 diabetes in insulin-resistant.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Prevalence of nephropathy, retinopathy, and neuropathy in subjects achieving all (A) three targets, (B) two targets, (C) one target, and (D) none, and.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Kaplan-Meier survival curves by severity of exacerbations in patients with COPD: (1) no acute exacerbations of COPD; (2) patients with acute exacerbations.

Presentation transcript:

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Probabilities of diabetes mellitus (DM) curves were compared using log-rank test (P<0.0001). Individuals at risk at each visit of follow-up were: 9306 (V0), 8230 (V1), 7524 (V2), 7178 (V3), 6582 (V4), 6229 (V5), 5572 (V6), 4876 (V7), 4275 (V8), 2931 (V9), and 510 (V10). William E Kraus et al. BMJ Open Diab Res Care 2018;6:e000523 ©2018 by American Diabetes Association